Discussion includes the discovery of agents for the treatment and management of bacterial infections, Parkinson′s disease, psoriasis, ulcers and stomach pain, atopic dermatitis, asthma, and cancer. Case studies examine the discovery of erythromycin analogs (antibiotics), Tagamet, and Ultiva (remifentanil). Full chapters are devoted to combinatorial chemistry, molecular biology–based drug discovery, genomics, and chemogenomics. Industrial chemists, biologists, biochemists, and business people in the pharmaceutical industry will all benefit from this authoritative reference.
The first volume of this set thoroughly describes conceptualizing a drug, creating a library of candidates for testing, screening those candidates for in vitro and in vivo activity, conducting and analyzing the results of clinical trials, and revising the drug as necessary.
The second volume describes optimizing the synthetic route; manufacturing, outsourcing, and marketing the drug, including coloring; and developing delivery methods.